Isomorphic Labs, the four-year old drug discovery start-up owned by Google parent Alphabet, will have an artificial intelligence-designed drug in trials by the end of this year, says its founder Sir Demis Hassabis.
“We’re looking at oncology, cardiovascular, neurodegeneration, all the big disease areas, and I think by the end of this year, we’ll have our first drug,” he said in an interview with the Financial Times at the World Economic Forum.
“It usually takes an average of five to 10 years [to discover] one drug. And maybe we could accelerate that 10 times, which would be an incredible revolution in human health,” said Hassabis, who received the Nobel Prize for chemistry with his colleague John Jumper and biochemist David Baker in October.
您已閱讀31%（749字），剩余69%（1686字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。